吡非尼酮与特发性肺纤维化患者肺癌发生风险:韩国全国人群研究
该研究基于韩国全国理赔数据库纳入9938例特发性肺纤维化(IPF)患者,采用倾向评分IPTW与landmark分析评估吡非尼酮使用与肺癌发生的关系。结果显示吡非尼酮组肺癌发生率更低(10.4 vs 27.9例/1000人年),加权校正HR 0.347(95%CI 0.258-0.466),单中心临床队列(n=941)结果一致。
要点
- IPF患者中吡非尼酮使用与肺癌发生风险降低独立相关(加权校正HR 0.347)。
- 倾向评分加权后吡非尼酮组肺癌发生率为10.4例/1000人年,低于未用组的27.9例/1000人年。
- 单中心IPF临床队列验证结果方向一致(加权校正HR 0.716)。
核心结论
- 吡非尼酮使用可能与IPF患者肺癌发生风险降低相关。
研究设计与样本
- 韩国全国理赔数据库纳入9938例IPF患者,采用倾向评分IPTW和landmark分析,并用Cox回归校正临床与社会经济变量。
- 另用单中心IPF临床队列(n=941)验证结果。
主要发现
- 患者平均年龄69.4岁,男性占73.7%,32.1%接受吡非尼酮。
- 中位随访3.0年期间766例发生肺癌(7.7%;21.9例/1000人年)。
- IPTW后吡非尼酮组肺癌发生率为10.4例/1000人年,低于未用组的27.9例/1000人年。
- 吡非尼酮使用与肺癌风险降低独立相关(加权校正HR 0.347,95%CI 0.258-0.466)。
- 单中心队列显示相似关联(加权校正HR 0.716,95%CI 0.517-0.991),且该关联在年龄或性别亚组中持续存在。
临床怎么用
- 对IPF患者处方吡非尼酮时,可将肺癌风险降低作为潜在额外获益信息纳入沟通与随访考量。
局限性
- 为观察性数据库研究,虽用IPTW和landmark分析,仍可能存在残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) carries a high risk of lung cancer, but the effect of pirfenidone on lung cancer development remains uncertain. We investigated the association between pirfenidone use and lung cancer development in patients with IPF. METHODS: We included 9938 patients with IPF from the Korean national claims database. Propensity score analysis with inverse probability of treatment weighting (IPTW) and landmark analyses were employed to evaluate lung cancer occurrence according to pirfenidone use. The association was evaluated using Cox regression models adjusted for clinical and socioeconomic variables. A single-centre IPF clinical cohort (n=941) was used for validating the findings. RESULTS: The mean patient age was 69.4 years, 73.7% were men and 32.1% received pirfenidone. Lung cancer developed in 766 patients with IPF (7.7%; 21.9 cases per 1000 person-years) during a median follow-up of 3.0 years. After IPTW, the pirfenidone group showed lower incidence (10.4 versus 27.9 cases per 1000 person-years) than the no pirfenidone group. Landmark analysis at 6 months after IPF diagnosis also showed lower incidence of lung cancer in the pirfenidone group than in the no pirfenidone group. Pirfenidone use was independently associated with a reduced lung cancer risk (weighted adjusted hazard ratio (HR) 0.347, 95% CI 0.258-0.466). A clinical cohort showed similar association (weighted adjusted HR 0.716, 95% CI 0.517-0.991). The association persisted across subgroups defined by age or sex. CONCLUSION: Pirfenidone use may be associated with a reduced lung cancer risk in patients with IPF.
引用
- Yoon HY, Kim H, Bae Y, et al. Pirfenidone and risk of lung cancer development in idiopathic pulmonary fibrosis: a nationwide population-based study. Eur Respir J. 2025. PMID: 39510556. doi:10.1183/13993003.01484-2024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。